Exparel was Pacira BioSciences’s largest product and service line in fiscal 2025, bringing in $575.13M of $726.41M (79%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Exparel | $536.90M | $538.12M | $548.96M | $575.13M | |||||
| Net Product Sales | — | — | — | — | |||||
| Product | — | — | — | — | |||||
| Exparel/Bupivacaine Liposome Injectable Suspension | — | — | — | — | |||||
| Zilretta | $105.52M | $111.10M | $118.09M | $116.63M | |||||
| Iovera° | $15.26M | $19.69M | $22.81M | $24.18M | |||||
| Bupivacaine Liposome Injectable Suspension | $6.48M | $3.34M | $7.32M | $6.91M | |||||
| Royalty Revenue | $2.67M | $2.73M | $3.78M | $3.56M | |||||
| Royalty | — | — | — | — | |||||
| Depocyte | — | — | — | — | |||||
| Collaborative Licensing & Milestone Revenue | — | — | — | — | |||||
| Total | $666.82M | $674.98M | $700.97M | $726.41M |
Pacira BioSciences brought in $726.41M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 3.6% from $700.97M in fiscal 2024. Exparel was the largest at $575.13M (79.2%), ahead of Zilretta at $116.63M (16.1%) and Iovera° at $24.18M (3.3%). The other two lines brought in $10.47M combined.
Compared with fiscal 2024, Iovera° grew fastest, up 6.0% to $24.18M, while Zilretta fell the most, down 1.2% to $116.63M. From fiscal 2022 to 2025, combined revenue from these lines grew from $666.82M to $726.41M, a compound annual growth rate of 2.9%. Exparel's share of the total fell from 80.5% to 79.2%.
Pacira BioSciences (PCRX) reports its revenue by product and service. In fiscal 2025, Exparel was its largest product and service line, bringing in $575.13M (79.2% of the total), followed by Zilretta at $116.63M (16.1%).
Exparel was Pacira BioSciences' largest product and service line in fiscal 2025, bringing in $575.13M, or 79.2% of the $726.41M total across its five product and service lines.
Among Pacira BioSciences' product and service lines that make up at least 2% of revenue, Iovera° grew fastest in fiscal 2025, up 6.0% from $22.81M to $24.18M.
Every figure comes from Pacira BioSciences' annual financial filings, as reported. Each line keeps the name Pacira BioSciences gives it, and years follow its fiscal calendar.
Pacira BioSciences' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.